[rev_slider slide1]
-
-
Mosaic Laboratories supports numerous translational medicine programs, and our biomarker data is presented to the FDA as evidence of drug activity and for patient pre-screening.
-
-
-
Mosaic Laboratories provides pre-clinical services including animal model, human tissue and cell line testing services.
-
-
-
Mosaic Laboratories offers clinical trial laboratory services for Phase I through Phase IV clinical trials. Mosaic supports clinical trials in the United States, Europe, Japan and other international locations.
-
Dr. Savala is a practicing pathologist who is board certified in hematopathology, anatomic and clinical pathology. Dr. Savala’s previous experience includes Director of Molecular Pathology for Cynogen (wholly owned… Read More
News
Bristol-Myers Squibb and Mosaic Laboratories (Referenced in Methods)
Yu H, Batenchuk C, Badzio A, Boyle TA, Czapiewski P, Chan DC, Lu X, et al.
PD-L1 Expression by Two Complementary Diagnostic Assays and mRNA In Situ Hybridization in Small Cell Lung Cancer. Thorac Oncol. 2017 Jan;12(1):110-120.
Bristol-Myers Squibb and Mosaic Laboratories (Referenced in Methods)
Sharma P, Retz M, Siefker-Radtke A, Baron A, Necchi A, Bedke J, et al.
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2017 Mar;18(3):312-322.
Bristol-Myers Squibb and Mosaic Laboratories (Referenced in Methods)
Weber JS, Gibney G, Sullivan RJ, Sosman JA, Slingluff CL, Lawrence DP, et al..
Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial. Lancet Oncol. 2016 Jul;17(7):943-55.
